Shares of Miragen Therapeutics Inc (NASDAQ:MGEN) saw strong trading volume on Monday . 5,182,784 shares were traded during mid-day trading, an increase of 2,185% from the previous session’s volume of 226,833 shares.The stock last traded at $1.36 and had previously closed at $0.91.
Several research analysts have weighed in on the company. Zacks Investment Research upgraded Miragen Therapeutics from a “hold” rating to a “strong-buy” rating and set a $1.25 price target for the company in a research note on Tuesday, August 13th. ValuEngine upgraded Miragen Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Wedbush reiterated a “buy” rating and set a $24.00 target price on shares of Miragen Therapeutics in a research report on Tuesday, May 21st. Finally, HC Wainwright initiated coverage on Miragen Therapeutics in a research report on Monday. They set a “buy” rating and a $3.00 target price for the company. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $13.15.
The company has a current ratio of 5.26, a quick ratio of 5.26 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $41.60 million, a P/E ratio of -1.22 and a beta of 1.12. The business has a 50-day moving average price of $1.81 and a 200 day moving average price of $2.51.
Miragen Therapeutics (NASDAQ:MGEN) last posted its earnings results on Wednesday, August 7th. The medical research company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.08. The firm had revenue of $2.51 million during the quarter, compared to the consensus estimate of $0.89 million. Miragen Therapeutics had a negative return on equity of 78.14% and a negative net margin of 925.52%. On average, sell-side analysts predict that Miragen Therapeutics Inc will post -1.15 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently modified their holdings of the stock. Bank of America Corp DE lifted its position in Miragen Therapeutics by 35.9% in the fourth quarter. Bank of America Corp DE now owns 33,116 shares of the medical research company’s stock worth $100,000 after buying an additional 8,756 shares during the last quarter. BlackRock Inc. lifted its position in Miragen Therapeutics by 3.4% in the fourth quarter. BlackRock Inc. now owns 1,459,881 shares of the medical research company’s stock worth $4,423,000 after buying an additional 48,128 shares during the last quarter. Deutsche Bank AG lifted its position in Miragen Therapeutics by 266.7% in the fourth quarter. Deutsche Bank AG now owns 190,653 shares of the medical research company’s stock worth $577,000 after buying an additional 138,657 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Miragen Therapeutics by 2.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 216,866 shares of the medical research company’s stock worth $657,000 after buying an additional 4,404 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in Miragen Therapeutics by 59.1% in the fourth quarter. Bank of New York Mellon Corp now owns 99,844 shares of the medical research company’s stock worth $302,000 after buying an additional 37,101 shares during the last quarter. Institutional investors own 37.35% of the company’s stock.
Miragen Therapeutics Company Profile (NASDAQ:MGEN)
Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan.
Read More: What is a front-end load?
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.